PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Memorial Sloan Kettering Cancer Center, University of Washington, Fred Hutch Cancer Center, Jena University Hospital, The University of Texas Southwestern Medical Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, The University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb (United States), Washington University in St. Louis
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4212988504